| Market Capitalization (Millions $) |
2,367 |
| Shares
Outstanding (Millions) |
354 |
| Employees |
160 |
| Revenues (TTM) (Millions $) |
32 |
| Net Income (TTM) (Millions $) |
-204 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Precigen Inc is a biotechnology company that utilizes its proprietary technologies to develop innovative solutions in the field of genetic engineering and synthetic biology. The company focuses on several key areas including gene therapy, gene editing, and the creation of novel genetic medicines.
They have developed a platform called UltraVector, which enables the rapid and precise engineering of genes, allowing for the creation of customized genetic constructs. Precigen Inc also specializes in developing and commercializing gene therapies for the treatment of various diseases, including cancer, cardiovascular disorders, and rare genetic diseases.
Additionally, Precigen Inc is involved in the development of next-generation technologies like CRISPR-Cas9 gene editing, which has the potential to revolutionize the treatment of genetic disorders by allowing for precise modifications to be made to the genome.
The company collaborates with academic institutions, pharmaceutical companies, and government agencies to accelerate the development and commercialization of their genetic technologies. Their mission is to improve the lives of patients by providing innovative genetic solutions and personalized treatments.
Company Address: 20374 Seneca Meadows Parkway Germantown, 20876 MD
Company Phone Number: 556-9900 Stock Exchange / Ticker: NASDAQ PGEN
|
2.41% 
321.09 %